

SECURITIES & EXCHANGE COMMISSION EDGAR FILING

Mymetics Corporation

Form: 8-K

Date Filed: 2011-10-04

Corporate Issuer CIK: 927761

Symbol: MYMX

SIC Code: 2836

Fiscal Year End: 12/31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 4, 2011 (May 23, 2011)

Mymetics Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State of other jurisdiction
of incorporation)

000-25132
(Commission
File Number)

25-1741849
(IRS Employer
Identification No.)

Route de la Corniche 4
1066 Epalinges, Switzerland
(Address of principal executive offices)

NA
(Zip Code)

Registrant's telephone number, including area code: +011 41 21 653 45 35

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events.

On May 23, 2011 the registrant ("Mymetics") received a letter from Abbott Laboratories agreeing to amend the existing License and Cooperation Agreements for Intranasal Delivery of APRECS based Vaccines and Virosomes based Vaccines between Mymetics B.V. and Abbott Biologicals B.V. ("Abbott") (formerly Solvay Pharamceuticals) to allow Mymetics to produce, commercialize and exploit its intra-nasal influenza vaccine technology and to use all data developed by Abbott under the license it had with Mymetics. Abbott had completed a successful phase I clinical study in Europe using Mymetics' intra-nasal influenza vaccine technology. Mymetics was negotiating a formal termination agreement with Abbott but recently determined upon consultation with Dutch counsel to rely on the May 23, 2011 letter between itself and Abbott to terminate its license agreement with Abbott with respect to the intra-nasal influenza vaccine. Mymetics has issued a press release regarding the termination of its license agreement with Abbott, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) *Exhibits.*

99.1 Press Release dated October 4, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MYMETICS CORPORATION

Date: October 4, 2011

By: /s/ Jacques-François Martin

Jacques-François Martin

President and Chief Executive Officer



Mymetics reclaims innovative intra-nasal influenza vaccine

Epalinges, Switzerland, 4 October 2011 – Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body's first line of defense, to prevent transmission of infectious diseases, announced today that it has been able to regain its innovative intra-nasal influenza vaccine from Solvay.

Ronald Kempers, CFO of Mymetics, commented: "We strongly believe in the intra-nasal flu vaccine and are delighted to have this important vaccine back in our vaccine portfolio which can provide Mymetics new opportunities to develop strategic partnerships with established and emerging vaccine producers".

"We believe that the good immune response developed by this inactivated non adjuvanted nasal vaccine and its ease of use will allow us to improve the immunization of children and the elderly," said Jacques-François Martin, the CEO of Mymetics.

Mymetics' had licensed its intra-nasal flu vaccine to Solvay which had developed the vaccine successfully until 2008, including the completion of a successful Phase I. Intranasal vaccination was found to be safe and well tolerated, and resulted in antibodies in the blood that exceeded the CHMP (Committee for Medicinal Products for Human Use) criteria for injected influenza vaccines.

A change in strategy and reprioritization at Solvay and the sale of Solvay Biologicals to Abbott Laboratories in 2010 resulted in Solvay suspending its development of Mymetics' innovative and promising intra-nasal vaccine product.

Mymetics has now been able to reclaim the intra-nasal flu vaccine product including all the clinical trial data, which will allow it to develop the vaccine further in the clinic and bring it to market with different strategic partners.

About Mymetics

Mymetics Corporation is a Swiss-based biotechnology company registered in the US (OTC BB: MYMX) developing next-generation preventative vaccines for infectious diseases. Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins, in combination with rationally designed antigens. The company's vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which for some pathogens may be essential for the development of an effective prophylactic vaccine. Mymetics currently has five vaccines in its pipeline: HIV-1/AIDS, Influenza, Respiratory Syncytial Virus, Malaria and Herpes Simplex Virus. The company's HIV-1 vaccine has completed a Phase I clinical trial in healthy human volunteers. A Phase 1b clinical trial for its Malaria vaccine on children in Tanzania has been completed, while RSV and HSV vaccine candidates are in the preclinical phase. For further information, please visit www.mymetics.com.

Contact

Ronald Kempers
CFO and COO
Mymetics Corporation
Tel: +41 21 653 4535

Media

Christophe Lamps
Senior Partner
Dynamics Group
Mobile: + 41 79 476 26 87
Email: cla@dynamicsgroup.ch

Forward-looking statements

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements, which are identified by the words "believe," "expect," "anticipate," "intend," "plan" and similar expressions. The statements contained herein which are not based on historical facts are forward-looking statements that involve known and unknown risks and uncertainties that could significantly affect our actual results, performance or achievements in the future and, accordingly, such actual results, performance or achievements may materially differ from those expressed or implied in any forward-looking statements made by or on our behalf. These risks and uncertainties include, but are not limited to, risks associated with our ability to successfully develop and protect our intellectual property, our ability to raise additional capital to fund future operations and compliance with applicable laws and changes in such laws and the administration of such laws. See Mymetics' most recent Form 10-K for a discussion of such risks, uncertainties and other factors. Readers are cautioned not to place undue reliance on these forward- looking statements which speak only as of the date the statements were made.
